基于转座子的癌基因整合在Abcb4(Mdr2)-/-小鼠中重现原发性硬化性胆管炎对胆管癌的高易感性
研究在10周龄Mdr2-/-小鼠(先天性PSC样病变)与健康野生型同窝仔中,分别经改良逆行胆道灌注或流体动力学尾静脉注射SB AKT/YAP1质粒系统。尾静脉注射在全部纤维化Mdr2-/-小鼠中诱导出高胆管癌负荷,肿瘤表型似人CCA并伴促结缔组织增生反应;TGFβ抑制可增强免疫浸润、降低肿瘤负荷并抑制胶原沉积。
要点
- 流体动力学尾静脉注射SB AKT/YAP1在全部纤维化Mdr2-/-小鼠中诱导出高胆管癌负荷。
- 逆行胆道注射SB AKT/YAP1在Mdr2-/-小鼠中仅26.67%(4/15)的肿瘤为胆管癌。
- 药理性抑制TGFβ较安慰剂增强免疫细胞肿瘤浸润、降低肿瘤负荷并抑制促结缔组织增生性胶原积聚。
核心结论
- 研究建立了新的高保真小鼠胆管癌模型SB CCA.Mdr2-/-,重现PSC中所见的胆道损伤与纤维化背景下胆管癌易感性增加。
研究设计与样本
- 10周龄Mdr2-/-小鼠(先天性PSC样病变)与健康野生型同窝仔接受改良逆行胆道灌注或流体动力学尾静脉注射SB AKT/YAP1质粒系统。
- 通过ALK5抑制剂(SB-525334)给药探究TGFβ的作用。
- 肿瘤表型、负荷与促结缔组织增生反应经组织学和RNA测序分析。
主要发现
- 逆行胆道注射SB AKT/YAP1在Mdr2-/-小鼠中仅26.67%(4/15)的肿瘤为胆管癌。
- 流体动力学尾静脉注射SB AKT/YAP1在全部纤维化Mdr2-/-小鼠中诱导出强肿瘤发生,较健康小鼠有高胆管癌负荷。
- 肿瘤表型似人胆管癌,表达多种胆管癌(而非肝细胞癌)标志物,并表现出显著的促结缔组织增生反应。
- RNA测序显示PSC样背景下演变的胆管癌出现深刻转录改变,多个免疫通路有特定改变。
- 药理性抑制TGFβ较安慰剂增强免疫细胞肿瘤浸润、降低肿瘤负荷并抑制促结缔组织增生性胶原积聚。
临床怎么用
- 作者认为SB CCA.Mdr2-/-模型可用于PSC-CCA生物学系统性研究和正式临床前药物测试。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC) that is difficult to diagnose and associated with high mortality. A lack of animal models of CCA recapitulating the hepatic microenvironment of sclerosing cholangitis has hindered the development of novel treatments. Herein, we sought to develop a mouse model of PSC-associated CCA. METHODS: Ten-week-old Mdr2-/- mice with congenital PSC-like disease, and healthy wild-type littermates were subjected to either modified retrograde biliary instillation or hydrodynamic tail vein injection of a sleeping beauty transposon-transposase plasmid system with activated AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes (SB AKT/YAP1). The role of TGFβ was interrogated via ALK5 inhibitor (SB-525334) administration. Tumor phenotype, burden and desmoplastic reaction were analyzed histologically and via RNA sequencing. RESULTS: While SB AKT/YAP1 plasmids administered via retrograde biliary injection caused tumors in Mdr2-/-, only 26.67% (4/15) of these tumors were CCA. Alternatively, hydrodynamic tail vein injection of SB AKT/YAP1 resulted in robust tumorigenesis in all fibrotic Mdr2-/- mice with high CCA burden compared to healthy mice. Tumors phenotypically resembled human CCA, expressed multiple CCA (but not hepatocellular carcinoma) markers, and exhibited a profound desmoplastic reaction. RNA sequencing analysis revealed profound transcriptional changes in CCA evolving in a PSC-like context, with specific alterations in multiple immune pathways. Pharmacological TGFβ inhibition led to enhanced immune cell tumor infiltration, reduced tumor burden and suppressed desmoplastic collagen accumulation compared to placebo. CONCLUSION: We established a new high-fidelity cholangiocarcinoma model in mice, termed SB CCA.Mdr2-/-, which recapitulates the increased susceptibility to CCA in the setting of biliary injury and fibrosis observed in PSC. Through transcriptomics and pharmacological studies, we show dysregulation of multiple immune pathways and TGFβ signaling as potential drivers of CCA in a PSC-like microenvironment. IMPACT AND IMPLICATIONS: Animal models for primary sclerosing cholangitis (PSC)-related cholangiocarcinoma (PSC-CCA) are lacking. Thus, we have developed and characterized a new mouse model of PSC-CCA, termed SB CCA.Mdr2-/-, which features reliable tumor induction on a PSC-like background of biliary injury and fibrosis. Global gene expression alterations were identified and standardized tools, including automated whole slide image analysis methodology for tumor burden and feature analysis, were established to enable systematic research into PSC-CCA biology and formal preclinical drug testing.
引用
- Huang P, Wei G, Kirkpatrick JD, et al. Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2024. PMID: 39089631. doi:10.1016/j.jhep.2024.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。